אבטוזמה 162 מ"ג תת-עורי - .Avtozma 162 mg s.c
| מינונים נוספים | |
|---|---|
| קבוצה פרמקולוגית (ATC4) | L04AC Interleukin inhibitors |
| מרכיב פעיל (ATC5) |
|
| צורת מתן | תת-עורי - S.C |
| צורת מינון | תמיסה להזרקה, SOLUTION FOR INJECTION למניעת מינון יתר או הרעלה יש ליטול את התרופה בהתאם למינון המומלץ כפי שמופיע בעלון לצרכן |
| התוויה | -AVTOZMA ® 162 MG/ML S.C. in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. In these patients, AVTOZMA ® 162 MG/ML S.C. can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.- AVTOZMA ® 162 MG/ML S.C. in combination with methotrexate (MTX) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX- AVTOZMA ® 162 MG/ML S.C. is indicated for the treatment of giant cell arteritis (GCA) in adult patients.-AVTOZMA ® 162 MG/ML S.C. in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. AVTOZMA ® 162 MG/ML S.C. can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.- AVTOZMA ® 162 MG/ML S.C. is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. AVTOZMA ® 162 MG/ML S.C. can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX. |
| עלון לרופא והחמרות לעלון |
אין עלון לרופא |
| עלון לצרכן |
|---|
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| אבטוזמה 162 מ"ג תת-עורי במאגר משרד הבריאות |
| חיפוש מאמרים | מאמרים ב-PubMed |
|---|---|
| מידע ברשת | RxList WebMD Drugs.com |
| שם יצרן | CELLTRION INC., SOUTH KOREA |
| שם בעל הרישום | PADAGIS ISRAEL AGENCIES LTD, ISRAEL |
| רישיון | רישיון מתאריך: 24/5/2026 |
| תאריך עדכון אחרון | 19/07/2026 |
